The molecular assay by dPCR was first established to specifically and accurately detect and quantify wild-type BRAF and variant BRAF in DNA from human follicular thyroid carcinoma–derived FTC-133 and papillary thyroid carcinoma–derived BCPAP cells. Here, BRAF is linked to thyroid gland follicular carcinoma.